print this page

Jay S. Steingrub, MD

Medicine Department   Image  
Critical Care Medicine Division
  • Vice-Chair of Research, Department of Medicine
  • Professor of Medicine, Tufts University School of Medicine
  • Director, Medical Intensive Care Unit
Baystate Critical Care Medicine
759 Chestnut Street
Springfield, MA 01199
  • Critical Care Research Fellowship
    University Health Center of Pittsburgh
    Pittsburgh, PA
  • Critical Care Fellowship
    University Health Center of Pittsburgh
    Pittsburgh, PA
  • Internal Medicine Residency
    Rochester General Hospital/University of Rochester
    Rochester School of Medicine and Dentistry
    Rochester, NY
  • State University of New York at Syracuse College of Medicine
    Syracuse, NY
Areas of Interest
  • Cytokine levels in septic hearts
  • Cardiac performance in shock states
  • Respiratory failure
  • Multi-organ system failure
Committee Appointments
  • Member, Department of Medicine Executive Committee
  • Vice Chair, Scientific Affairs and Research Committee, Dept of Medicine
  • Chair, Hospital Medicine Chief Search Committee
  • Member, The Rays of Hope for Breast Cancer Research Review Board
Professional Service
  • Ad Hoc Reviewer, Cleveland Clinic Journal of Medicine
  • Reviewer, Journal Intensive Care Medicine
  • Reviewer, Critical Care Medicine
  • Reviewer, American Journal of Medicine
  • Reviewer, Critical Care Forum
  • Member, CHEST Editorial Board Board
  • Reviewer, Journal of Postgraduate Medicine
  • Wheeler A, Steingrub J, Schmidt GA et al:  A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis:  Comparison with a controlled clinical trial.  Crit Care Med 2008;36(1):14-23.
  • Esteban A, Ferguson ND, Meade MO et al (Steingrub JS Site Investigator):  Evolution of mechanical ventilation in response to clinical research. [Review] Am J Respir Crit Care Med 2008;177(2):170-177.
  • Taylor Thompson B, Orme JF, Steingrub JS et al:  Multicenter validation of a computer-based clinical decision support tool for glucose control in adult and pediatric intensive care unit.  J Diabetes Science and Technology 2008;2(3):357-368.
  • Morris AH, Orme J, Truwit JD, Steingrub JS, Tidswell MA et al:  A replicable method for blood glucose control in critically ill patients.  Crit Care Med 2008;36(8):1787-1795.
  • Kinasewitz GT, Privalle CT, Imm A, Steingrub JS et al:  Multi-center, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock.  Crit Care Med 2008;36(7):1999-2007.
  • Liu KD, Levitt J, Zhuo H, Steingrub JS et al:  Randomized clinical trial of activated protein C for the treatment of acute lung injury.  Amer J Respir Crit Car Med 2008;178:618-623.
  • Robertson TE, Mann HJ, Hyzy R, Partner for Excellence in Critical Care (Steingrub JS, Higgins TL, Mailloux PM) et al:  Multicenter implementation of a consensus-developed, evidence-based, spontaneous breathing trial protocol.  Crit Care Med 2008;36(10):2758-2762.
  • Erickson SE, Shipak MG, Martin GS, ARDS Clinical Trial Network Clinical Centers, et al (Steingrub JS, Tidswell M):  Racial and ethnic disparities in mortality from acute lung injury.  Crit Care Med 2009;37(1):1-6.
  • Vincent J-L, Rello J, Marshall J et al for the EPIC H Group of Investigators (Steingrub JS):  International study of the prevalence and outcomes of infection in intensive care units.  JAMA 2009 (December):302;2323-2329.
  • Grissom CK, Morris AH, Lanken PN, Ancukiewicz M, Orme JF, Schoenfeld Thompson BT, for the National Institutes of Health/National Heart, Lung and blood Institute Acute Respiratory Distress Syndrome Network(Steingrub, JS, Tidswell, M).  Association of physical examination with pulmonary artery catheter parameters in acute lung injury.  Crit Care Med 2009;37(10):2720-2726.
  • Lindenauer PK, Rothberg MB, Nathanson BH, Pekow PS, Steingrub JS:  Activated protein C and hospital mortality in septic shock:  A propensity-matched analysis.  Crit Care Med April 2010;38(4):1101-1107.
  • Xeus Inestigators:  Steingrub JS, Cheatham ML, Woodward B, Wang HT, Effron MB: A prospective, observational study of Xigris use in the United States (XEUS).  Journal of Critical Care 2010;25(4):660.e9--660.e16.
  • Lagu T, Rothberg MB, Nathanson BH, Pekow PS, Steingrub JS, Lindenauer PK:  The relationship between hsopial spending and mortality in patients with sepsis.  Arch Intern Med 2011;171(4):292-299.
  • Rice TW, Ware LB, Haponik EF, Steingrub JS et al:  Vascular pedicle width in acute lung injury:  correlation with intravascular pressures and ability to discriminate fluid status.  Critical Care 2011;15(2):R86.
  • Liu K, thompson BT, Ancukiewicz M Steingrub JS et al for the National Institutes of Health National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome Network:  Acute kidney injury in patients with acute lung iHnjury: Impact of fluid accumulation on classification of acute kidney injury and associated outcomes.  Crit Care Med 2011;39(12):1-7.
  • Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK:  Hospitalizations, costs and outcomes of severe sepsis in the United States 2003 to 2007.  Crit Care Med March Mar;2012;40(3):754-761.
  • Morris P, Steingrub J, Huang B, Tang S, Liu P, Rhode P, Wong H.  A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome.  BMC  Pulmonary Medicine Feb;2012;12(1):5.
  • Lagu T., Rothberg M.B., Nathanson B.H., Steingrub J.S., Lindenauer P.K. Incorporating initial treatments improves performance of a mortality prediction model for patients with sepsis. Pharmacoepidemiology and Drug Safety 2012; May;21(Suppl 2):44-52.
  • Lagu T., Rothberg M.B., Nathanson B.H., Pekow P.S., Steingrub J.S., Lindenauer P.K. Variation in the care of septic shock: The impact of patient and hospital characteristics. Journal of Critical Care Aug;2012;27(4):329-36.
  • The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network (member of Writing Committee: J Steingrub).  Initial trophic vs. full enteral feeding in patients with acute lung injury; the EDEN randomized trial.  JAMA Feb;2012;307(8):795-803.
  • Andrzejewski C, Popovsky M, Stec T, Provencher J, O’Hearn L, Visintainer P, Steingrub J.  Hemotherapy bedside biovigilance involving vital sign values and characteristics of patients with suspected transfusion reactions associated with fluid challenges:  can some cases of transfusion-associated circulatory overload have proinflammatory aspects?  Transfusion 2012: DOI:10.1111/j.1537-2995.2012.03595.x
  • Blagev DP, Hirshberg EL, Sward K, Steingrub JS et al:  The evolution of eProtocols that enable reproducible clinical research and care methods.  J Clin Monit Comput Aug;2012;26(4)305-17.
  • Lagu T, Rothberg MB, Shieh MS, Pekow PS, Steingrub JS, Lindenauer PK:  What is the best method for estimating the burden of severe sepsis in the United States?  J Crit Care 2012 Aug;27(4):414.e1-9.
  • Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR 3rd, Higgs E, Randolph AG, Smoot BE, Thompson BT, NHLBI ARDS Network (Steingrub JSS):  Critical illness from 2009 pandemic influenza A virus and bacterial co-infection in the United States.  Crit Care Med 2012 May 40(5):1487-1498.
  • Pelosi P, Ferguson ND, Frutos-Vivar F, Anzueto A, Putensen C, Paymondos K, Apezteguia C, Desmery P, Hurtado J, Abroug F, Elizalde J, Tomicic V, Cakar N, Gonzalez M, Arabi Y, Moreno R, Esteban A. Ventila Study Group (Steingrub JSS): Crit Care Med 2011 June 39(6):1482-1492.
  • Rice T, Wheeler A, Thompson B, Steingrub J, Hite R, Moss M, Moris A, Dong N, Rock P, National Heart Lung and Blood Institute Acute Respiratory Distress syndrome (ARDS), Clinical Trials Network: Initial trophic vs full enteral feeding in patients with acute lung injury: The EDEN randomized trial.  JAMA 2012 Feb ;307:795-803.
  • Agrawal A, Zhuo H, Brady S, Levitt J, Steingrub J, et al.  Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity illness:  results from two clinical trials.  Am J Physiol Lung Cell Mol Physiol 2012;Oct; 303(8):L634-9. doi: 10.1152/ajplung.00195.2012.
  • OASIS:  A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis.  Agennix, Inc., 2011-present,  Site Principal Investigator, Multicenter Trial
  • *A Randomized Double-Blind Placebo-Controlled Trial of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Lung Injury.  National Heart Lung and Blood Institute (NHLBI), 2010-2013, Site Principle Investigator
  • *Identifying Effective Strategies to Disclose Prognosis in Patients with Acute Lung Injury – No. 1R01HL094553-01, NHLBI, 2010-2013; Site Principal Investigator, Multicenter Trial
  • Efficacy and Safety Evaluation of ALT-836 (formerly TNX-832, Sunol-cH36) In Patients with Infection-Induced Acute Lung Injury/Acute Respiratory Distress \ Syndrome. Altor Bioscience Corporation,  2009-2010, Site Principal Investigator
  •  A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis.  Aggenix,  2008-2009, Site Principal Investigator